As COVID-19 vaccine availability improves in low- and middle-income countries, there is an urgent need to identify and rapidly scale up strategies that optimize vaccine access and uptake among vulnerable populations, including people living with HIV (PLHIV) and members of key populations most affected by HIV. This session will share the latest evidence on safety and effectiveness of COVID-19 vaccines for PLHIV, including dosage and booster recommendations; explore barriers to more equitable vaccine access and uptake among PLHIV and key populations; and highlight locally-led vaccine rollout approaches that leverage lessons from the global HIV response and the existing HIV program infrastructure to effectively accelerate COVID-19 vaccine coverage among PLHIV and key populations.

• Presentations
• Session recording (English)